PDIA3 and lung cancer: PDIA3 mutations have implications in lung cancer via abnormal immunosurveillance [45], while FOXP3 acts as a co‐activator in NSCLC, promoting Wnt/β‐catenin signaling, epithelial‐mesenchymal transition, and metastasis [46].